KRAS G12R in pancreatic cancer: why this mutation resists current inhibitor strategies

Sep 22, 2026

Uploaded by Elsa

KRAS G12R in pancreatic ductal adenocarcinoma (PDAC) remains therapeutically challenging despite limited progress from decades of cytotoxic chemotherapy. Around 90% of PDAC tumors carry activating KRAS mutations, yet the G12R glycine-to-arginine substitution (15–20%) does not mirror the clinical success of KRAS G12C inhibitors. A focused narrative review analyzes structural, biochemical, and clinical evidence describing Switch II pocket occlusion, distinct signaling rewiring, and survival advantages such as amplified autophagy, limiting pocket-directed inhibitor and MEK blockade efficacy. The review highlights emerging panRAS(ON) ternary complex inhibitors as potential pocket-bypass strategies.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Abstract

Background

Methods

Results

Conclusions

Implications for Practice

Introduction

The Oncologist, 2026, 31, oyag155 [https://doi.org/10.1093/oncolo/oyag155](https://doi.org/10.1093/oncolo/oyag155) [Published: June 2](Published: June 2), 2026 Review Article KRAS G12R in pancreatic cancer: why this mutation resists current inhibitor strategies Kenneth A. Kern, MD, MPH, MS*,1, 1Affiliate Faculty, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA 92109, United States *Corresponding author: Kenneth A. Kern, MD, MPH, MS, Affiliate Faculty, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, and Oncology Breakthrough Advisory Group, 1804 Garnet Ave, Suite 701, San Diego, CA 92109, USA ([info@oncologybreakthrough.com](info@oncologybreakthrough.com)) . Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal solid malignancies, with limited therapeutic progress despite decades of cytotoxic chemotherapy. About 90% of PDAC tumors harbor activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS), making oncogenic KRAS signaling a longstanding therapeutic target. Although KRAS G12C inhibitors have demonstrated clinical success in lung and colorectal cancers, this strategy has not translated to the same degree in the glycine-to-arginine substitution at codon 12 (G12R), present in 15%-20% of PDAC tumors. Methods: A focused narrative review of the literature was conducted using PubMed and Google Scholar to examine structural, biochemical, and clinical data relevant to KRAS G12R, binding pocket dynamics, therapeutic outcomes, and novel approaches. Results: G12R substitution introduces a bulky, positively charged arginine side chain that sterically occludes the binding pocket of KRAS (Switch II pocket), precluding both covalent and competitive inhibitor engagement. In addition to structural inaccessibility, G12R mutations exhibit distinct signaling rewiring, including impaired phosphoinositide 3-kinase alpha (PI3Kα) and mitogen-activated protein kinase (MEK) interactions, along with increased survival driven by amplified autophagy. These features limit the efficacy of pocket-directed inhibitors and downstream MEK blockade. Emerging panRAS(ON) ternary complex inhibitors bypass the occluded pocket by recruiting cyclophilin A to block effector signaling and may provide an effective means to address KRAS G12R-mutated disease. Conclusions: KRAS G12R defines a structurally and biologically distinct subset of PDAC characterized by binding-pocket occlusion and increased survival pathways. Effective treatment will require pocket-independent strategies or targeting of G12R-specific biological vulnerabilities. Key words: KRAS G12R; pancreatic neoplasms; Switch II pocket; molecular targeted therapy; neoplasm drug resistance; pancreatic ductaladenocarcinoma Implications for Practice KRAS G12R defines a subset of pancreatic ductal adenocarcinoma that is genomically and biologically distinct from other KRASmutated diseases and is resistant to current KRAS-targeted therapies. Unlike other KRAS mutations, the G12R substitution disrupts the structural integrity of the pharmacologic binding site on KRAS known as the Switch II pocket, preventing efficacy from pocket-directed inhibitors. Clinical attempts to inhibit this binding pocket in G12R have yet to produce durable or meaningful clinical benefit. Recognizing KRAS G12R as a distinct molecular entity can help clinicians better understand the biological constraints that limit therapeutic success in this subset of pancreatic cancer. Received: February 20, 2026. Accepted: April 17, 2026 © The Author(s) 2026. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted reuse, distribution, and reproduction in any medi

FAQs

Why does the KRAS G12R mutation resist current KRAS-targeted inhibitor strategies in PDAC?

G12R introduces a bulky, positively charged arginine that sterically occludes the Switch II binding pocket, preventing covalent and competitive inhibitor engagement and reducing downstream therapeutic impact.

What structural and signaling changes are associated with KRAS G12R beyond pocket occlusion?

KRAS G12R shows distinct signaling rewiring, including impaired PI3Kα and MEK interactions, alongside increased survival driven by amplified autophagy.

What treatment approach does the article suggest for KRAS G12R–mutated disease?

Effective therapy will likely require pocket-independent strategies or targeting KRAS G12R-specific vulnerabilities; emerging panRAS(ON) ternary complex inhibitors may bypass the occluded pocket by recruiting cyclophilin A to block effector signaling.

Sep 22, 2026

Uploaded by Elsa